<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR136">
 <label>136.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Taylor</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Kotian</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Warren</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Panchal</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Bavari</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Julander</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Dobo</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Rose</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>El-Kattan</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Taubenheim</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Babu</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Sheridan</surname>
    <given-names>WP</given-names>
   </name>
  </person-group>
  <article-title>BCX4430â€”a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease</article-title>
  <source>J Infect Public Health</source>
  <year>2016</year>
  <volume>9</volume>
  <issue>3</issue>
  <fpage>220</fpage>
  <lpage>226</lpage>
  <pub-id pub-id-type="doi">10.1016/j.jiph.2016.04.002</pub-id>
  <?supplied-pmid 27095300?>
  <pub-id pub-id-type="pmid">27095300</pub-id>
 </element-citation>
</ref>
